Bristol-Myers wins US Opdivo approval three months early
This article was originally published in Scrip
The US FDA granted accelerated approval for Bristol-Myers Squibb's programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) for the treatment of advanced melanoma more than three months earlier than expected.
You may also be interested in...
Tesaro's ovarian cancer treatment performed better in patients with BRCA mutation, but FDA did not restrict indication, leaving decision to providers.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.